Grifols (GIKLY) Cash & Current Investments (2010 - 2025)
Grifols (GIKLY) reported Cash & Current Investments of $965.0 million for Q4 2025, down 8.41% on a YoY basis from $1.1 billion in Q4 2024, and down 8.41% quarter-over-quarter from $1.1 billion in Q4 2024.
Grifols (GIKLY) Cash & Current Investments (2010 - 2025) Analysis & Trends
Grifols has reported Cash & Current Investments for 16 years, with the latest figure at $965.0 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Current Investments fell 8.41% year-over-year to $965.0 million; the trailing twelve-month figure through Dec 2025 stood at $965.0 million (down 8.41% YoY), and the FY2025 full-year result was $965.0 million, down 8.41% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $965.0 million, down from $1.1 billion in the prior quarter.
- The five-year high for Cash & Current Investments was $5.4 billion in Q4 2021, with the low at $594.6 million in Q4 2023.
- Historically, Cash & Current Investments has averaged $1.7 billion across 5 years, with a median of $965.0 million in 2025.
- Annual changes were most pronounced in 2021 — Cash & Current Investments surged 678.94% — and 2022, when it tumbled 88.77%.
- Grifols' Cash & Current Investments stood at $5.4 billion in 2021, then plunged by 88.77% to $604.7 million in 2022, then decreased by 1.66% to $594.6 million in 2023, then soared by 77.2% to $1.1 billion in 2024, then declined by 8.41% to $965.0 million in 2025.
- The last three Cash & Current Investments figures came in at $965.0 million (Q4 2025), $1.1 billion (Q4 2024), and $594.6 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.38 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 10.49 Bn |
| 10 | Grifols | - | - | - | 964.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 964.99 Mn |
| Dec 31, 2024 | 1.05 Bn |
| Dec 31, 2023 | 594.61 Mn |
| Dec 31, 2022 | 604.66 Mn |
| Dec 31, 2021 | 5.38 Bn |
| Dec 31, 2020 | 691.11 Mn |
| Sep 30, 2020 | 1.22 Bn |
| Mar 31, 2020 | -115.85 Mn |
| Dec 31, 2019 | 1.12 Bn |
| Sep 30, 2019 | 884.51 Mn |
| Mar 31, 2019 | -339.22 Mn |
| Dec 31, 2018 | 1.20 Bn |
| Sep 30, 2018 | 736.73 Mn |
| Jun 30, 2018 | 781.56 Mn |
| Mar 31, 2018 | 34.33 Mn |
| Dec 31, 2017 | 1.06 Bn |
| Jun 30, 2017 | 825.49 Mn |
| Mar 31, 2017 | 156.72 Mn |
| Dec 31, 2016 | 969.15 Mn |
| Sep 30, 2016 | 1.01 Bn |